ABSTRACT
Chronic periaortitis (CP) is a rare disease characterised by the presence of a fibro-inflammatory tissue typically enveloping the abdominal aorta, the iliac arteries and, in some cases, the nearby structures, such as the ureters and the inferior vena cava. Imaging plays a key role in the diagnosis and follow-up: computed tomography and magnetic resonance imaging scans are used to define the extension of the pathological tissue, whereas fluorodeoxyglucose positron emission tomography is the gold standard to establish the degree of its metabolic activity. CP must be distinguished from secondary forms of periaortic infiltration, which include malignant, infectious, and drug-related aetiologies. This review focuses on the clinical aspects of CP and the differential diagnosis with secondary cases, and aims to provide the clinician with a guide through this challenging clinical approach.
Subject(s)
Retroperitoneal Fibrosis , Humans , Retroperitoneal Fibrosis/diagnosis , Retroperitoneal Fibrosis/therapy , Retroperitoneal Fibrosis/complications , Aorta, Abdominal/pathology , Tomography, X-Ray Computed , Diagnosis, Differential , Magnetic Resonance ImagingABSTRACT
A study has been carried out in the Ivory Coast to assess the efficacy of a combined vaccine against yellow fever and measles relative to that of each vaccine administered separately. Healthy children aged six to nine months were recruited and divided into two age groups: less than seven months (group I) and more than eight months (group II). In each group, they were randomly assigned to receive either yellow fever vaccine only (A), measles vaccine only (B), or the combined vaccine (C). The serological responses to measles and yellow fever were assessed in 219 initially seronegative children 45 days after immunization. More than 90% of the children developed yellow fever haemagglutination inhibiting antibodies. Neither age nor combination with measles vaccine influenced the responses to yellow fever vaccine. Measles haemagglutinational inhibiting antibodies were found in 97% of the children and the seroconversion rate was influenced neither by age nor by combination with yellow fever vaccine. Younger infants had lower titres of measles antibody. No particular adverse reactions were notified during the follow up. This study shows that combined yellow fever and measles vaccines are immunogenic in infants from the age of six months. Controlling yellow fever in endemic areas and the prevention of measles in young infants may greatly benefit by this combination.
Subject(s)
Measles Vaccine/administration & dosage , Viral Vaccines/administration & dosage , Yellow fever virus/immunology , Antibodies, Viral/biosynthesis , Clinical Trials as Topic , Cote d'Ivoire , Humans , Infant , Measles/prevention & control , Measles Vaccine/adverse effects , Viral Vaccines/adverse effects , Yellow Fever/prevention & controlABSTRACT
The first outbreak caused by Igbo Ora virus is described. Virus circulation has been demonstrated up on thirty-three sick persons in Yamoussoukro area (Ivory Coast).
